This randomized controlled trial enrolled 254 individuals diagnosed with schizophrenia spectrum disorders. The intervention consisted of 10-session virtual reality-based cognitive behavioral therapy for psychosis (VR-CBTp) compared against standard cognitive behavioral therapy for psychosis (CBTp). Follow-up occurred at end-of-treatment. Setting was not reported. Publication type was not reported.
Primary analysis focused on end-of-treatment paranoia. Secondary outcomes included avolition, safety behavior, delusion severity, cognitive biases, negative other-beliefs, age, gender, education, occupation, diagnosis, social anxiety, depression, anhedonia, total negative symptoms, functioning, core beliefs, and interpersonal trauma. Higher baseline avolition, safety behavior, delusion severity, and cognitive biases were associated with end-of-treatment paranoia across treatments. Interaction analyses showed individuals with high avolition improved more in VR-CBTp than CBTp. Participants with moderate-to-high delusion severity improved more in VR-CBTp, whereas those with lower delusion severity showed better outcomes in CBTp.
No demographic or other clinical characteristics were significantly associated with outcome. Moderation analyses revealed interactions for negative other-beliefs, though direction was not reported. Safety data, including adverse events and discontinuations, were not reported. The study is noted as exploratory with modest effects and largely nonsignificant findings.
Both CBTp and VR-CBTp appear suitable for a wide range of individuals with paranoia, highlighting the importance of considering patient preferences and limitations.
View Original Abstract ↓
BACKGROUND: This exploratory study examined baseline characteristics modifying treatment effects on paranoia in individuals diagnosed with schizophrenia spectrum disorders following a 10-session virtual reality-based cognitive behavioral therapy for psychosis (VR-CBTp) or standard CBTp.
METHODS: All participants in the FaceYourFears trial were included (=254; CBTp =128; VR-CBTp =126). General linear and logistic regression models examined baseline variables associated with end-of-treatment paranoia. In covariate analyses, regression coefficients quantified associations across treatments. In moderation analyses, interaction terms (randomization x moderator) were tested, with corresponding regression coefficients estimated and assessed at the 25th (low), 50th (medium), and 75th (high) percentiles of continuous variables.
RESULTS: Across treatments, higher baseline avolition, safety behavior, delusion severity, and cognitive biases were associated with end-of-treatment paranoia. Moderation analyses revealed interactions for avolition, delusion severity, and negative other-beliefs. Although avolition and delusion severity were associated with poorer outcomes overall, individuals with high avolition and those with moderate-to-high delusion severity improved more in VR-CBTp than CBTp, whereas participants with lower delusion severity showed better outcomes in CBTp. No demographic (age, gender, education, and occupation) or other clinical characteristics (diagnosis, paranoia, social anxiety, depression, anhedonia, total negative symptoms, functioning, core beliefs, or interpersonal trauma) were significantly associated with outcome.
CONCLUSIONS: This exploratory study generates hypotheses for future research, including VR-CBTp's potential to engage individuals with high avolition. Given the modest effects and largely nonsignificant findings, both CBTp and VR-CBTp appear suitable for a wide range of individuals with paranoia, highlighting the importance of considering patient preferences.